Alaunos Therapeutics, Inc. - TCRT STOCK NEWS

Alaunos Therapeutics to wind down TCR-T Library trial and focus on hunTR® platform, reducing workforce by 60%

Alaunos Therapeutics, Inc. announced that they will present early translational data from their ongoing TCR-T Library Phase 1/2 trial at the ASCO Annual Meeting. The data highlights the effectiveness and safety of their non-viral TCR-T cell therapy in treating solid tumors with high-frequency driver mutations. Two out of three patients showed anti-tumor activity, with one achieving a partial response and another achieving stable disease. TCR persistence and tumor infiltration were observed in patients, indicating the potential of this therapy. More data will be provided in the third quarter of 2023.

Alaunos Therapeutics, Inc. (TCRT), a leader in T-cell receptor (TCR) cell therapy, announced a poster presentation for its lead Sleeping Beauty TCR-T cell therapy program at the 2023 ASCO Annual Meeting from June 2-6, 2023, in Chicago. The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation study conducted at MD Anderson Cancer Center, focusing on patients with solid tumors, including non-small cell lung and colorectal cancers, who have specific targeted driver mutations. The poster will detail the safety and efficacy of TCR-T cells targeting shared KRAS and TP53 mutations. The presentation is scheduled for June 3, 2023, showcasing Alaunos' advancements in TCR therapy for cancer treatment.

Alaunos Therapeutics (Nasdaq: TCRT) announced the appointment of Robert J. Hofmeister, PhD, as Chief Scientific Officer of the Board of Directors, effective immediately. Hofmeister replaces Chris Bowden, MD. With over 25 years of expertise in T-cell therapy, Hofmeister previously led scientific teams at TCR² Therapeutics and played a crucial role in developing their TRuC^®-T cell platform. Alaunos aims to advance its TCR-T Library Phase 1/2 trial targeting solid tumors. The company benefits from its proprietary Sleeping Beauty cell engineering platform and industry-leading library of TCRs. The ongoing collaboration with the National Cancer Institute supports its research and development efforts.

Alaunos Therapeutics (Nasdaq: TCRT), a prominent T-cell receptor cell therapy company, announced its participation in two upcoming investor conferences. The first is Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, featuring fireside chats and one-on-one meetings. The second is the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, which will include a company presentation and one-on-one meetings. A live webcast of the Needham presentation will be available on Alaunos' website for 90 days post-event. Alaunos is advancing TCR therapies for solid tumors and collaborates with the National Cancer Institute.

Alaunos Therapeutics (TCRT) announced transformative advancements in TCR-T cell therapy for solid tumors, showcasing promising clinical results. The company successfully enrolled patients in its TCR-T Library Phase 1/2 trial, with expectations to report interim data by mid-2023. Its TCR library has doubled, integrating new TCRs that enhance market reach. Manufacturing efficiency has improved, decreasing processing times by 13%. Financially, Alaunos reported a net loss of $9.2 million for Q4 2022, down from $11.8 million year-over-year. With $53 million in cash reserves, the company anticipates sufficient funding into Q4 2023.